Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves for pain relief? ultrasound device tested for fibromyalgia

NCT ID NCT07361328

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new, noninvasive ultrasound device to see if it can reduce pain and other symptoms in people with fibromyalgia. About 50 adults with fibromyalgia will receive 6 treatment sessions over 2 weeks. Researchers will measure pain levels and symptom impact using questionnaires and MRI scans, tracking results for up to 60 days after the first treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets American College of Rheumatology criteria for fibromyalgia: * Generalized pain, defined as pain in at least 4 of 5 regions, is present. * Widespread pain index (WPI) ≥ 7 and symptom severity scale score (SSS) ≥ 5, or WPI of 4-6 and SSS score ≥ 9. * Symptoms have been present at a similar level for at least 3 months. * d.A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses * Failure of at least two evidence based medications (i.e., pregabalin, duloxetine, milnacipran) for the treatment of fibromyalgia. * Failure of one or more attempts at physical therapy including: * Aerobic exercise like walking, cycling, and swimming, * Water therapy/hydrotherapy with warm water exercises, * Tai Chi involving slow, controlled movements, * Yoga, * Resistance training, * Bodyweight exercises, * Pilates, * Myofascial release therapy applying gentle pressure on trigger points, * Massage therapy, * Trigger point therapy targeting specific pain points, * Joint mobilization, * Postural retraining to correct body alignment, * Balance and coordination exercises, * Feldenkrais method for movement awareness, * Alexander technique to enhance posture and movement efficiency, * Transcutaneous Electrical Nerve Stimulation (TENS) for pain relief, * Heat therapy using hot packs, infrared, or paraffin wax, * Cold therapy with ice packs or cryotherapy, * Ultrasound therapy for deep tissue relaxation, * Biofeedback to control muscle tension and pain response, * Gentle static stretching for prolonged duration, * Active dynamic stretching for full range of motion, * Proprioceptive Neuromuscular Facilitation (PNF) stretching, * Hydrotherapy pool exercises, * Ai Chi (water-based Tai Chi), * Underwater treadmill therapy, * Graded motor imagery (GMI), * Mirror therapy to retrain brain-body connections, * Mindfulness-based stress reduction (MBSR) combining meditation and movement, * Cognitive-behavioral therapy * Gaze stabilization techniques for dizziness and disorientation * Pain score of ≥ 4 on Numerical Rating Scale (NRS-11) at Screening visit. * Pain score of ≥ 4 on Numerical Rating Scale (NRS-11) at Baseline visit. * Stated willingness and ability to comply with all study procedures, to receive no additional interventions, and to remain on the same psychiatric treatment regimen (e.g., medication, psychotherapy) beginning at least one (1) month prior to screening and for the duration of the main study period unless a change in treatment is recommended or agreed upon by the site principal investigator. * For participants of reproductive potential: negative urine or blood pregnancy test at screening; agreement to use a highly effective method of contraception (≤ 1% pregnancy rate) including tubal ligation, vasectomized partner, IUD or IUS (intrauterine device or system), or long-acting contraceptives (LARC). * Willing and able to provide informed consent Exclusion Criteria: * Any previous diagnosis of bipolar disorder or schizophrenia-spectrum disorder during the participant's lifetime, according to Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-5) criteria. * Diagnosis of moderate or severe alcohol or other substance use disorder in the past 6 months, according to DSM-5 criteria. * Diagnosis of obsessive compulsive disorder and/or posttraumatic stress disorder in the past 30 days, according to DSM-5 criteria, and which is unstable in the clinical judgment of the investigator. * Primary diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder in the past 3 months, according to DSM-5 criteria. * Clinically significant neurodevelopmental, neurocognitive, or personality disorder, according to DSM-5 criteria. * Moderate-High Risk of Suicide, according to the Columbia-Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (i.e., answers YES to Question 3 and NO to Question 6 (Moderate Risk), or YES to Question 4, 5, or 6 (High Risk)), or in the clinical judgement of the site principal investigator (PI).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia (FM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pain Research Center, University of Utah

    RECRUITING

    Salt Lake City, Utah, 84108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.